Resources
Plasmid Files

pCMV6-AN-FP602

PrecisionShuttle™ mammalian expression vector for fusing an ORF to an N-terminal TurboFP602 tag.

To see this sequence with restriction sites, features, and translations, please download
 SnapGene or the free  SnapGene Viewer.

pCMV6-AN-FP602 Sequence and MappCMV6-AN-FP602.dna
Map and Sequence File   
Sequence Author:  OriGene
Download Free Trial Get SnapGene Viewer

 AanI (6550) XmnI (5872) AlwNI (4796) PciI (4380) BstZ17I (4001) BsmI (3949) AanI (3888) PfoI (3804) BstBI (3711) PflFI - Tth111I (3147) NdeI (592) SnaBI (698) VP1.5 (forward primer) (839 .. 856) Eco53kI (924) SacI (926) EcoRI (979) BamHI (992) Acc65I (998) KpnI (1002) PasI (1250) Bsu36I (1285) PshAI (1659) BspEI (1725) AsiSI - SgfI (1741) MreI - SgrAI (1743) AscI (1747) HindIII (1761) RsrII (1778) MluI (1784) NotI (1794) PaeR7I - PspXI - XhoI (1802) PmeI (1811) FseI (1821) SacII (1825) XL39 (reverse primer) (1917 .. 1936) EcoO109I (2041) BbvCI - Bpu10I (2137) BlpI (2181) BsmBI (2201) AgeI (2399) XcmI (2494) SexAI * (2586) StuI (2818) AvrII (2819) BsaBI * (2888) KasI (3028) NarI (3029) SfoI (3030) PluTI (3032) PstI (3082) pCMV6-AN-FP602 6622 bp
AanI  (6550)
2 sites
T T A T A A A A T A T T
XmnI  (5872)
1 site
G A A N N N N T T C C T T N N N N A A G
AlwNI  (4796)
1 site
C A G N N N C T G G T C N N N G A C

Sticky ends from different AlwNI sites may not be compatible.
PciI  (4380)
1 site
A C A T G T T G T A C A

PciI is inhibited by nonionic detergents.
BstZ17I  (4001)
1 site
G T A T A C C A T A T G
BsmI  (3949)
1 site
G A A T G C N C T T A C G N

Sticky ends from different BsmI sites may not be compatible.
AanI  (3888)
2 sites
T T A T A A A A T A T T
PfoI  (3804)
1 site
T C C N G G A A G G N C C T

Sticky ends from different PfoI sites may not be compatible.
BstBI  (3711)
1 site
T T C G A A A A G C T T
PflFI  (3147)
1 site
G A C N N N G T C C T G N N N C A G

The 1-base overhangs produced by PflFI may be hard to ligate.
Sticky ends from different PflFI sites may not be compatible.
Tth111I  (3147)
1 site
G A C N N N G T C C T G N N N C A G

The 1-base overhangs produced by Tth111I may be hard to ligate.
Sticky ends from different Tth111I sites may not be compatible.
NdeI  (592)
1 site
C A T A T G G T A T A C

Prolonged incubation with NdeI may lead to removal of additional
nucleotides.
SnaBI  (698)
1 site
T A C G T A A T G C A T
Eco53kI  (924)
1 site
G A G C T C C T C G A G
SacI  (926)
1 site
G A G C T C C T C G A G
EcoRI  (979)
1 site
G A A T T C C T T A A G
BamHI  (992)
1 site
G G A T C C C C T A G G

After cleavage, BamHI-HF™ (but not the original BamHI) can
remain bound to DNA and alter its electrophoretic mobility.
Acc65I  (998)
1 site
G G T A C C C C A T G G
KpnI  (1002)
1 site
G G T A C C C C A T G G
PasI  (1250)
1 site
C C C W G G G G G G W C C C

Sticky ends from different PasI sites may not be compatible.
Bsu36I  (1285)
1 site
C C T N A G G G G A N T C C

Sticky ends from different Bsu36I sites may not be compatible.
PshAI  (1659)
1 site
G A C N N N N G T C C T G N N N N C A G

PshAI quickly loses activity at 37°C, but can be used at 25°C for
long incubations.
BspEI  (1725)
1 site
T C C G G A A G G C C T
AsiSI  (1741)
1 site
G C G A T C G C C G C T A G C G
SgfI  (1741)
1 site
G C G A T C G C C G C T A G C G
MreI  (1743)
1 site
C G C C G G C G G C G G C C G C
SgrAI  (1743)
1 site
C R C C G G Y G G Y G G C C R C

Efficient cleavage requires at least two copies of the SgrAI
recognition sequence.
AscI  (1747)
1 site
G G C G C G C C C C G C G C G G
HindIII  (1761)
1 site
A A G C T T T T C G A A
RsrII  (1778)
1 site
C G G W C C G G C C W G G C

Efficient cleavage requires at least two copies of the RsrII
recognition sequence.
Sticky ends from different RsrII sites may not be compatible.
For full activity, add fresh DTT.
MluI  (1784)
1 site
A C G C G T T G C G C A
NotI  (1794)
1 site
G C G G C C G C C G C C G G C G
PaeR7I  (1802)
1 site
C T C G A G G A G C T C

PaeR7I does not recognize the sequence CTCTCGAG.
PspXI  (1802)
1 site
V C T C G A G B B G A G C T C V
XhoI  (1802)
1 site
C T C G A G G A G C T C
PmeI  (1811)
1 site
G T T T A A A C C A A A T T T G
FseI  (1821)
1 site
G G C C G G C C C C G G C C G G

FseI gradually loses activity when stored at -20°C.
SacII  (1825)
1 site
C C G C G G G G C G C C

Efficient cleavage requires at least two copies of the SacII
recognition sequence.
EcoO109I  (2041)
1 site
R G G N C C Y Y C C N G G R

Sticky ends from different EcoO109I sites may not be compatible.
BbvCI  (2137)
1 site
C C T C A G C G G A G T C G
Bpu10I  (2137)
1 site
C C T N A G C G G A N T C G

Efficient cleavage requires at least two copies of the Bpu10I
recognition sequence.
This recognition sequence is asymmetric, so ligating sticky ends
generated by Bpu10I will not always regenerate a Bpu10I site.
Sticky ends from different Bpu10I sites may not be compatible.
BlpI  (2181)
1 site
G C T N A G C C G A N T C G

Sticky ends from different BlpI sites may not be compatible.
BsmBI  (2201)
1 site
C G T C T C N G C A G A G N ( N ) 4

Sticky ends from different BsmBI sites may not be compatible.
AgeI  (2399)
1 site
A C C G G T T G G C C A

AgeI quickly loses activity at 37°C, but can be used at 25°C for
long incubations.
XcmI  (2494)
1 site
C C A N N N N N N N N N T G G G G T N N N N N N N N N A C C

The 1-base overhangs produced by XcmI may be hard to ligate.
Sticky ends from different XcmI sites may not be compatible.
SexAI  (2586)
1 site
A C C W G G T T G G W C C A
* Blocked by Dcm methylation.
Sticky ends from different SexAI sites may not be compatible.
StuI  (2818)
1 site
A G G C C T T C C G G A
AvrII  (2819)
1 site
C C T A G G G G A T C C
BsaBI  (2888)
1 site
G A T N N N N A T C C T A N N N N T A G
* Blocked by Dam methylation.
KasI  (3028)
1 site
G G C G C C C C G C G G
NarI  (3029)
1 site
G G C G C C C C G C G G

Efficient cleavage requires at least two copies of the NarI
recognition sequence.
SfoI  (3030)
1 site
G G C G C C C C G C G G
PluTI  (3032)
1 site
G G C G C C C C G C G G

Efficient cleavage requires at least two copies of the PluTI
recognition sequence.
PstI  (3082)
1 site
C T G C A G G A C G T C
VP1.5 (forward primer)
18-mer  /  44% GC
1 binding site
839 .. 856  =  18 annealed bases
Tm  =  51°C
XL39 (reverse primer)
20-mer  /  55% GC
1 binding site
1917 .. 1936  =  20 annealed bases
Tm  =  59°C
AmpR
5200 .. 6060  =  861 bp
286 amino acids  =  31.6 kDa
   Segment 2:  
   5200 .. 5991  =  792 bp
   263 amino acids  =  28.9 kDa
Product: β-lactamase
confers resistance to ampicillin, carbenicillin, and
related antibiotics
AmpR
5200 .. 6060  =  861 bp
286 amino acids  =  31.6 kDa
   Segment 1:  signal sequence  
   5992 .. 6060  =  69 bp
   23 amino acids  =  2.6 kDa
Product: β-lactamase
confers resistance to ampicillin, carbenicillin, and
related antibiotics
AmpR
5200 .. 6060  =  861 bp
286 amino acids  =  31.6 kDa
2 segments
Product: β-lactamase
confers resistance to ampicillin, carbenicillin, and
related antibiotics
NeoR/KanR
2901 .. 3695  =  795 bp
264 amino acids  =  29.0 kDa
Product: aminoglycoside phosphotransferase from
Tn5
confers resistance to neomycin, kanamycin, and
G418 (Geneticin®)
NeoR/KanR
2901 .. 3695  =  795 bp
264 amino acids  =  29.0 kDa
Product: aminoglycoside phosphotransferase from
Tn5
confers resistance to neomycin, kanamycin, and
G418 (Geneticin®)
TurboFP602
1020 .. 1724  =  705 bp
235 amino acids  =  26.3 kDa
Product: red-shifted derivative of red fluorescent
protein from Entacmaea quadricolor
mammalian codon-optimized
TurboFP602
1020 .. 1724  =  705 bp
235 amino acids  =  26.3 kDa
Product: red-shifted derivative of red fluorescent
protein from Entacmaea quadricolor
mammalian codon-optimized
hGH poly(A) signal
1854 .. 2476  =  623 bp
human growth hormone polyadenylation signal
hGH poly(A) signal
1854 .. 2476  =  623 bp
human growth hormone polyadenylation signal
ori
4441 .. 5029  =  589 bp
high-copy-number ColE1/pMB1/pBR322/pUC origin
of replication
ori
4441 .. 5029  =  589 bp
high-copy-number ColE1/pMB1/pBR322/pUC origin
of replication
f1 ori
6192 .. 25  =  456 bp
f1 bacteriophage origin of replication; arrow
indicates direction of (+) strand synthesis
f1 ori
6192 .. 25  =  456 bp
f1 bacteriophage origin of replication; arrow
indicates direction of (+) strand synthesis
CMV enhancer
343 .. 722  =  380 bp
human cytomegalovirus immediate early enhancer
CMV enhancer
343 .. 722  =  380 bp
human cytomegalovirus immediate early enhancer
SV40 promoter
2505 .. 2834  =  330 bp
SV40 enhancer and early promoter
SV40 promoter
2505 .. 2834  =  330 bp
SV40 enhancer and early promoter
CMV promoter
723 .. 926  =  204 bp
human cytomegalovirus (CMV) immediate early
promoter
CMV promoter
723 .. 926  =  204 bp
human cytomegalovirus (CMV) immediate early
promoter
SV40 poly(A) signal
3869 .. 3990  =  122 bp
SV40 polyadenylation signal
SV40 poly(A) signal
3869 .. 3990  =  122 bp
SV40 polyadenylation signal
AmpR promoter
6061 .. 6165  =  105 bp
AmpR promoter
6061 .. 6165  =  105 bp
MCS
1725 .. 1827  =  103 bp
multiple cloning site
MCS
1725 .. 1827  =  103 bp
multiple cloning site
T7 promoter
952 .. 970  =  19 bp
promoter for bacteriophage T7 RNA polymerase
T7 promoter
952 .. 970  =  19 bp
promoter for bacteriophage T7 RNA polymerase
SV40 ori
2685 .. 2820  =  136 bp
SV40 origin of replication
SV40 ori
2685 .. 2820  =  136 bp
SV40 origin of replication
Try SnapGene and create your own beautiful maps

Individual Sequences & Maps

SnapGene offers the fastest and easiest way to plan, visualize, and document your molecular biology procedures.

Priced accessibly so that everyone in your lab can have a license.

Learn More...

SnapGene Viewer is a versatile tool for creating and sharing richly annotated sequence files. It opens many common file formats.

Free! Because there should be no barriers to seeing your data.

Learn More...

The map, notes, and annotations on this page and in the sequence/map file are copyrighted material. This material may be used without restriction by academic, nonprofit, and governmental entities, except that the source must be cited as "www.snapgene.com/resources". Commercial entities must contact GSL Biotech LLC for permission and terms of use.

Copyright © 2016 GSL Biotech LLC | Site Map | Privacy | Legal Disclaimers   Subscribe to Our Newsletter